SlideShare a Scribd company logo
1 of 8
Why should you invest in
                Omega Pharma?



Gorik François   Artevelde Hogeschool   2AT02
Contents
Financial analysis
Consolidated income statement
Capital injection
Innovation
Conclusion
Sources
 Financial analysis
                 500
                 450
                 400
                 350
                 300
                 250                                                        1H2012
                 200                                                        1H2011
                 150
                 100
                  50
                   0
                           1           2            3           4




  Key financial figures for the first half of 2012 Year on year evolution        1H2012        1H2011

  Consolidated turnover                            +4%                               471,2         454,4

  Gross margin                                     +6%                               244,7         231,3

  EBITDA                                           +27%                                   82        64,7

  Operating profit                                 +35%                                   51        37,8
 Consolidated income statement


    Consolidated turnover      Year on year evolution
    Net Sales                  +4%
    Cost of goods sold         +1%
    Gross Margin               +6%
    Operating Profit           +35%
    Finance income             +9%
    Finance cost               +39%
    Net Finance cost           +40%
    Result before income tax   +33%
    Income tax expense         +38%
    Result after income tax    +32%
 Capital injection

   • ±5,2 million new shares
   • 190 million EUR injected




   Total assets (in EUR thousand)                          1 969 363   1 495 707
   Equity                                                  850 362     633 215
   Share capital and share premium                         557 706     367 706
   Retained earnings                                       417 437     388 475
   Treasury shares                                         -118 730    -118 730
   Fair value and other reserves                           -5 572      -2 972
   Cumulative translation adjustments                      -465        -1 261
   Equity attributable to the shareholders of the parent   850 376     633 218
   company
   Equity attributable to non-controlling interests        -14         -3
 Innovation


   New products/brands in the
   following five categories:

   •   Derma
   •   Cough & Cold
   •   Parasites
   •   Classics
   •   Multi Locals
 Conclusion

•   New branches and products
•   The net sales grew with 4%
•   New shares in the company
•   Joint venture with a South-African company
 Sources

• http://omega-
  pharma.be.res7.mijnpreview.com/uploads/962/120822%20Omega%20Pharma
  %20Interim%20Financial%20Report%201H2012.pdf

More Related Content

What's hot

1 q15 arezzo_apresentacao_call ing v2
1 q15 arezzo_apresentacao_call ing v21 q15 arezzo_apresentacao_call ing v2
1 q15 arezzo_apresentacao_call ing v2
Arezzori
 
Victrex - Full Year Results 2013
Victrex - Full Year Results 2013Victrex - Full Year Results 2013
Victrex - Full Year Results 2013
Company Spotlight
 

What's hot (13)

Qliro Group Q1 2015
Qliro Group Q1 2015Qliro Group Q1 2015
Qliro Group Q1 2015
 
Klöckner & Co SE - HY 1 2014 Results - Analysts' and Investors' Conference
Klöckner & Co SE - HY 1 2014 Results - Analysts' and Investors' Conference Klöckner & Co SE - HY 1 2014 Results - Analysts' and Investors' Conference
Klöckner & Co SE - HY 1 2014 Results - Analysts' and Investors' Conference
 
1 q15 arezzo_apresentacao_call ing v2
1 q15 arezzo_apresentacao_call ing v21 q15 arezzo_apresentacao_call ing v2
1 q15 arezzo_apresentacao_call ing v2
 
Full year results presentation (final excluding script)
Full year results presentation (final excluding script)Full year results presentation (final excluding script)
Full year results presentation (final excluding script)
 
CDON Group Q2 2013 presentation
CDON Group Q2 2013 presentationCDON Group Q2 2013 presentation
CDON Group Q2 2013 presentation
 
Q2 2018 financial release presentation v1.0
Q2 2018 financial release presentation v1.0Q2 2018 financial release presentation v1.0
Q2 2018 financial release presentation v1.0
 
Q2 2018 financial release presentation v1.0
Q2 2018 financial release presentation v1.0Q2 2018 financial release presentation v1.0
Q2 2018 financial release presentation v1.0
 
Victrex - Full Year Results 2013
Victrex - Full Year Results 2013Victrex - Full Year Results 2013
Victrex - Full Year Results 2013
 
Novoenzymes Group Financial Statement2005
Novoenzymes  Group Financial Statement2005Novoenzymes  Group Financial Statement2005
Novoenzymes Group Financial Statement2005
 
Q2 2013 Investor Conference Call Presentation Charts
Q2 2013 Investor Conference Call Presentation ChartsQ2 2013 Investor Conference Call Presentation Charts
Q2 2013 Investor Conference Call Presentation Charts
 
Qliro group presentation Q1 2017
Qliro group presentation Q1 2017Qliro group presentation Q1 2017
Qliro group presentation Q1 2017
 
Cdon group 2014 q3
Cdon group 2014 q3Cdon group 2014 q3
Cdon group 2014 q3
 
Klöckner & Co - German Corporate Conference 2013
Klöckner & Co - German Corporate Conference 2013Klöckner & Co - German Corporate Conference 2013
Klöckner & Co - German Corporate Conference 2013
 

Viewers also liked (10)

Ludovic Depoortere at the Marketing Shower
Ludovic Depoortere at the Marketing ShowerLudovic Depoortere at the Marketing Shower
Ludovic Depoortere at the Marketing Shower
 
Presentazione omega pharma
Presentazione omega pharmaPresentazione omega pharma
Presentazione omega pharma
 
2011-05-22 Domain Driven Design
2011-05-22 Domain Driven Design2011-05-22 Domain Driven Design
2011-05-22 Domain Driven Design
 
Financial analysis Omega Pharma
Financial analysis Omega PharmaFinancial analysis Omega Pharma
Financial analysis Omega Pharma
 
Clasificación UCI Pro Tour DDC
Clasificación UCI Pro Tour DDCClasificación UCI Pro Tour DDC
Clasificación UCI Pro Tour DDC
 
Davy de vlieger at the Marketing Shower
Davy de vlieger at the Marketing ShowerDavy de vlieger at the Marketing Shower
Davy de vlieger at the Marketing Shower
 
Ed OTC Marketing Seminar 2008
Ed OTC Marketing Seminar 2008Ed OTC Marketing Seminar 2008
Ed OTC Marketing Seminar 2008
 
Omega Pharma
Omega PharmaOmega Pharma
Omega Pharma
 
Pharmaceutical marketing course
Pharmaceutical marketing coursePharmaceutical marketing course
Pharmaceutical marketing course
 
Pharmaceutical Marketing Management
Pharmaceutical Marketing ManagementPharmaceutical Marketing Management
Pharmaceutical Marketing Management
 

Similar to Omega pharma

2006 12-21 Q1 2006/2007 Results
2006 12-21 Q1 2006/2007 Results2006 12-21 Q1 2006/2007 Results
2006 12-21 Q1 2006/2007 Results
KappAhl
 
2008 04-02 Q2 & Half-Year 2007/2008 Results
2008 04-02 Q2 & Half-Year 2007/2008 Results2008 04-02 Q2 & Half-Year 2007/2008 Results
2008 04-02 Q2 & Half-Year 2007/2008 Results
KappAhl
 
Wolters Kluwer 2005 Half-Year Results
Wolters Kluwer 2005 Half-Year ResultsWolters Kluwer 2005 Half-Year Results
Wolters Kluwer 2005 Half-Year Results
Wolters Kluwer
 
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
Deutsche EuroShop AG
 
2012 Full-Year Results presentation
2012 Full-Year Results presentation2012 Full-Year Results presentation
2012 Full-Year Results presentation
Wolters Kluwer
 
Colgate AR_ 2001
Colgate AR_ 2001Colgate AR_ 2001
Colgate AR_ 2001
finance19
 
XING AG half year report 2012
XING AG half year report 2012XING AG half year report 2012
XING AG half year report 2012
XING SE
 
Q1 2012
Q1 2012Q1 2012
Q1 2012
Sweco
 
Generali Group 2014 First Half Results
Generali Group 2014 First Half ResultsGenerali Group 2014 First Half Results
Generali Group 2014 First Half Results
Generali
 
Balda GB 2011 englisch
Balda GB 2011 englischBalda GB 2011 englisch
Balda GB 2011 englisch
Balda AG
 
Terna 2012-2016 Strategic Plan
Terna 2012-2016 Strategic PlanTerna 2012-2016 Strategic Plan
Terna 2012-2016 Strategic Plan
Terna SpA
 

Similar to Omega pharma (20)

2006 12-21 Q1 2006/2007 Results
2006 12-21 Q1 2006/2007 Results2006 12-21 Q1 2006/2007 Results
2006 12-21 Q1 2006/2007 Results
 
Gunnebo Interim Report Jan-Sep 2012
Gunnebo Interim Report Jan-Sep 2012Gunnebo Interim Report Jan-Sep 2012
Gunnebo Interim Report Jan-Sep 2012
 
2008 04-02 Q2 & Half-Year 2007/2008 Results
2008 04-02 Q2 & Half-Year 2007/2008 Results2008 04-02 Q2 & Half-Year 2007/2008 Results
2008 04-02 Q2 & Half-Year 2007/2008 Results
 
Wolters Kluwer 2005 Half-Year Results
Wolters Kluwer 2005 Half-Year ResultsWolters Kluwer 2005 Half-Year Results
Wolters Kluwer 2005 Half-Year Results
 
Wolters Kluwer 2012 Half-Year Investor Presentation
Wolters Kluwer 2012 Half-Year Investor PresentationWolters Kluwer 2012 Half-Year Investor Presentation
Wolters Kluwer 2012 Half-Year Investor Presentation
 
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
Deutsche EuroShop - Conference Call Presentation - Interim Report Q1 2012
 
2012 Full-Year Results presentation
2012 Full-Year Results presentation2012 Full-Year Results presentation
2012 Full-Year Results presentation
 
Resultados banco popular
Resultados banco popularResultados banco popular
Resultados banco popular
 
Presentation 2012
Presentation 2012Presentation 2012
Presentation 2012
 
Colgate AR_ 2001
Colgate AR_ 2001Colgate AR_ 2001
Colgate AR_ 2001
 
Q2 2012
Q2 2012Q2 2012
Q2 2012
 
XING AG half year report 2012
XING AG half year report 2012XING AG half year report 2012
XING AG half year report 2012
 
Resultados bayer
Resultados bayerResultados bayer
Resultados bayer
 
Kemira financial statements bulletin 2012
Kemira financial statements bulletin 2012Kemira financial statements bulletin 2012
Kemira financial statements bulletin 2012
 
SGS | 2012 Half Year Results
SGS | 2012 Half Year ResultsSGS | 2012 Half Year Results
SGS | 2012 Half Year Results
 
Q1 2012
Q1 2012Q1 2012
Q1 2012
 
Generali Group 2014 First Half Results
Generali Group 2014 First Half ResultsGenerali Group 2014 First Half Results
Generali Group 2014 First Half Results
 
Balda GB 2011 englisch
Balda GB 2011 englischBalda GB 2011 englisch
Balda GB 2011 englisch
 
Terna 2012-2016 Strategic Plan
Terna 2012-2016 Strategic PlanTerna 2012-2016 Strategic Plan
Terna 2012-2016 Strategic Plan
 
Electrolux Consolidated results 2012
Electrolux Consolidated results 2012Electrolux Consolidated results 2012
Electrolux Consolidated results 2012
 

Recently uploaded

VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
dipikadinghjn ( Why You Choose Us? ) Escorts
 
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
dipikadinghjn ( Why You Choose Us? ) Escorts
 
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
dipikadinghjn ( Why You Choose Us? ) Escorts
 
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
dipikadinghjn ( Why You Choose Us? ) Escorts
 

Recently uploaded (20)

VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
VIP Call Girl Service Andheri West ⚡ 9920725232 What It Takes To Be The Best ...
 
WhatsApp 📞 Call : 9892124323 ✅Call Girls In Chembur ( Mumbai ) secure service
WhatsApp 📞 Call : 9892124323  ✅Call Girls In Chembur ( Mumbai ) secure serviceWhatsApp 📞 Call : 9892124323  ✅Call Girls In Chembur ( Mumbai ) secure service
WhatsApp 📞 Call : 9892124323 ✅Call Girls In Chembur ( Mumbai ) secure service
 
(INDIRA) Call Girl Mumbai Call Now 8250077686 Mumbai Escorts 24x7
(INDIRA) Call Girl Mumbai Call Now 8250077686 Mumbai Escorts 24x7(INDIRA) Call Girl Mumbai Call Now 8250077686 Mumbai Escorts 24x7
(INDIRA) Call Girl Mumbai Call Now 8250077686 Mumbai Escorts 24x7
 
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
TEST BANK For Corporate Finance, 13th Edition By Stephen Ross, Randolph Weste...
 
The Economic History of the U.S. Lecture 23.pdf
The Economic History of the U.S. Lecture 23.pdfThe Economic History of the U.S. Lecture 23.pdf
The Economic History of the U.S. Lecture 23.pdf
 
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
VIP Call Girl in Mumbai 💧 9920725232 ( Call Me ) Get A New Crush Everyday Wit...
 
Booking open Available Pune Call Girls Wadgaon Sheri 6297143586 Call Hot Ind...
Booking open Available Pune Call Girls Wadgaon Sheri  6297143586 Call Hot Ind...Booking open Available Pune Call Girls Wadgaon Sheri  6297143586 Call Hot Ind...
Booking open Available Pune Call Girls Wadgaon Sheri 6297143586 Call Hot Ind...
 
Shrambal_Distributors_Newsletter_Apr-2024 (1).pdf
Shrambal_Distributors_Newsletter_Apr-2024 (1).pdfShrambal_Distributors_Newsletter_Apr-2024 (1).pdf
Shrambal_Distributors_Newsletter_Apr-2024 (1).pdf
 
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
05_Annelore Lenoir_Docbyte_MeetupDora&Cybersecurity.pptx
 
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Koregaon Park Call Me 7737669865 Budget Friendly No Advance Booking
 
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
VIP Independent Call Girls in Andheri 🌹 9920725232 ( Call Me ) Mumbai Escorts...
 
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
VIP Independent Call Girls in Mumbai 🌹 9920725232 ( Call Me ) Mumbai Escorts ...
 
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbaiVasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
Vasai-Virar Fantastic Call Girls-9833754194-Call Girls MUmbai
 
The Economic History of the U.S. Lecture 30.pdf
The Economic History of the U.S. Lecture 30.pdfThe Economic History of the U.S. Lecture 30.pdf
The Economic History of the U.S. Lecture 30.pdf
 
The Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdfThe Economic History of the U.S. Lecture 18.pdf
The Economic History of the U.S. Lecture 18.pdf
 
Gurley shaw Theory of Monetary Economics.
Gurley shaw Theory of Monetary Economics.Gurley shaw Theory of Monetary Economics.
Gurley shaw Theory of Monetary Economics.
 
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
VVIP Pune Call Girls Katraj (7001035870) Pune Escorts Nearby with Complete Sa...
 
02_Fabio Colombo_Accenture_MeetupDora&Cybersecurity.pptx
02_Fabio Colombo_Accenture_MeetupDora&Cybersecurity.pptx02_Fabio Colombo_Accenture_MeetupDora&Cybersecurity.pptx
02_Fabio Colombo_Accenture_MeetupDora&Cybersecurity.pptx
 
Indore Real Estate Market Trends Report.pdf
Indore Real Estate Market Trends Report.pdfIndore Real Estate Market Trends Report.pdf
Indore Real Estate Market Trends Report.pdf
 
The Economic History of the U.S. Lecture 19.pdf
The Economic History of the U.S. Lecture 19.pdfThe Economic History of the U.S. Lecture 19.pdf
The Economic History of the U.S. Lecture 19.pdf
 

Omega pharma

  • 1. Why should you invest in Omega Pharma? Gorik François Artevelde Hogeschool 2AT02
  • 2. Contents Financial analysis Consolidated income statement Capital injection Innovation Conclusion Sources
  • 3.  Financial analysis 500 450 400 350 300 250 1H2012 200 1H2011 150 100 50 0 1 2 3 4 Key financial figures for the first half of 2012 Year on year evolution 1H2012 1H2011 Consolidated turnover +4% 471,2 454,4 Gross margin +6% 244,7 231,3 EBITDA +27% 82 64,7 Operating profit +35% 51 37,8
  • 4.  Consolidated income statement Consolidated turnover Year on year evolution Net Sales +4% Cost of goods sold +1% Gross Margin +6% Operating Profit +35% Finance income +9% Finance cost +39% Net Finance cost +40% Result before income tax +33% Income tax expense +38% Result after income tax +32%
  • 5.  Capital injection • ±5,2 million new shares • 190 million EUR injected Total assets (in EUR thousand) 1 969 363 1 495 707 Equity 850 362 633 215 Share capital and share premium 557 706 367 706 Retained earnings 417 437 388 475 Treasury shares -118 730 -118 730 Fair value and other reserves -5 572 -2 972 Cumulative translation adjustments -465 -1 261 Equity attributable to the shareholders of the parent 850 376 633 218 company Equity attributable to non-controlling interests -14 -3
  • 6.  Innovation New products/brands in the following five categories: • Derma • Cough & Cold • Parasites • Classics • Multi Locals
  • 7.  Conclusion • New branches and products • The net sales grew with 4% • New shares in the company • Joint venture with a South-African company
  • 8.  Sources • http://omega- pharma.be.res7.mijnpreview.com/uploads/962/120822%20Omega%20Pharma %20Interim%20Financial%20Report%201H2012.pdf